-
May 24, 2012
The European Commission/pharmaceutical industry's Innovative Medicines Initiative (IMI) is launching a 223.7 million euro programme today. aimed at tackling antibiotic resistance and speeding up the delivery of new antibiotics to patients.
-
May 24, 2012
Bayer has suffered a setback after advisors to the US Food and Drug Administration narrowly voted against expanding the label on its Johnson & Johnson-partnered anticoagulant Xarelto
-
May 24, 2012
GlaxoSmithKline could walk away from its $2.60 billion bid to buy Human Genome Sciences if the latter's board does not drop a 'poison pill' adopted last week to thwart the UK drug giant's hostile approach
-
May 24, 2012
Takeda says that regulators in Europe have agreed to review its type 2 diabetes therapy alogliptin, a month after receiving a knockback from the FDA
-
May 22, 2012
Talks between Pfizer and a consortium led by property company London & Metropolitan International Developments over the sale of the drug giant's Sandwich site in Kent have ended without a deal
-
May 23, 2012
Around 163 essential medicines are now unavailable from pharmacies in Greece, sector leaders have said, ahead of the nation's pharmacists' planned one-day strike on May 23.
-
May 23, 2012
The French biotechnology sector is in need of new growth solutions as companies struggle to finance themselves
-
May 23, 2012
Eli Lilly has presented promising mid-stage data on its investigational diabetes drug dulaglutide which confirmed its cardiovascular safety profile
-
May 23, 2012
The chances of Pfizer's tafamidis getting approval in the USA have been hurt after staff at the Food and Drug Administration recommended against giving the green light to the treatment for patients with transthyretin familial amyloid polyneuropathy
-
May 22, 2012
Just after staff at the US Food and Drug Administration made positive noises about expanding the label on Xarelto, one of Bayer's other key drugs, Nexavar, has failed in a late-stage lung cancer trial